Skip to main content

Sublingual misoprostol versus intravenous oxytocin in prevention of post-partum hemorrhage

Archives of Gynecology and Obstetrics volume 289, pages 739–742 (2014)Cite this article

Abstract

Background

Post-partum hemorrhage (PPH) is the most common direct cause of maternal mortality and timely intervention can save many lives.

Objective

To compare the effectiveness of sublingual misoprostol to intravenous oxytocin in preventing post-partum hemorrhage in low risk vaginal birth.

Methods

One hundred patients with no risk factor for PPH were randomly allocated to receive 600 μg misoprostol administered sublingually or 10 IU of intravenous oxytocin immediately after the delivery of baby. Main outcome measures were post-partum blood loss, drop in hemoglobin in 24 h, duration of third stage of labor, and drug-related adverse effects.

Results

Mean age, parity and gestational age were similar in both groups. Mean blood loss was significantly lower in oxytocin group (114.28 ± 26.75 versus 149.50 ± 30.78 ml; p = 0.00). Drop in hemoglobin was 0.31 ± 0.16 versus 0.49 ± 0.21 g% (p = 0.01) in oxytocin and misoprostol group, respectively. Duration of third stage labor was shorter in oxytocin group (median 5 min, IQR: 4.5–5.5 versus 5.5 min, IQR: 5–6 min, p < 0.01). Although fever and shivering were common adverse effects with misoprostol but were not clinically significant.

Conclusion

Intravenous oxytocin is more efficacious than sublingual misoprostol in preventing PPH in institutional deliveries.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Potts M, Prata N, Sahin–Hodoglugil NN (2010) Maternal mortality: one death every 7 min. Lancet 375:1762–1763

    PubMed  Article  Google Scholar 

  2. Mathai M, Gulmezoglu AM, Hill S (2007) Saving womens lives: evidence-based recommendations for the prevention of postpartum haemorrhage. Bull World Health Organ 85:322–323

    PubMed Central  PubMed  Google Scholar 

  3. Rogers J, Wood J, McCandlish R, Ayers S, Truesdale A, Elbourne D (1998) Active versus expectant management of third stage of labour: the Hinchingbrooke randomised controlled trial. Lancet 351:693–699

    CAS  PubMed  Article  Google Scholar 

  4. Aflaifel N, Weeks AD (2012) Active management of the third stage of labour. BMJ 345:e4546

    PubMed  Article  Google Scholar 

  5. McDonald SJ, Middleton P (2008) Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. Cochrane Database Syst Rev CD004074

  6. Gulmezoglu AM, Lumbiganon P, Landoulsi S, Widmer M, Abdel–Aleem H, Festin M et al (2012) Active management of the third stage of labour with and without controlled cord traction: a randomised, controlled, non-inferiority trial. Lancet 379:1721–1727

    PubMed  Article  Google Scholar 

  7. Winikoff B, Dabash R, Durocher J, Darwish E, Nguyen TN, Leon W et al (2010) Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. Lancet 375:210–216

    CAS  PubMed  Article  Google Scholar 

  8. Roach MK, Abramovici A, Tita AT (2012) Dose and duration of oxytocin to prevent postpartum hemorrhage: a review. Am J Perinatol

  9. Carroli G, Cuesta C, Abalos E, Gulmezoglu AM (2008) Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol 22:999–1012

    PubMed  Article  Google Scholar 

  10. Tang OS, Gemzell–Danielsson K, Ho PC (2007) Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 99(Suppl 2):S160–S167

    CAS  PubMed  Article  Google Scholar 

  11. (2011) The selection and use of essential medicines. World Health Organ Tech Rep Ser i–xiv, pp 1–249

  12. Hofmeyr GJ, Gulmezoglu AM, Novikova N, Linder V, Ferreira S, Piaggio G (2009) Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects. Bull World Health Organ 87:666–677

    PubMed Central  PubMed  Article  Google Scholar 

  13. Tuncalp O, Hofmeyr GJ, Gulmezoglu AM (2012) Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev 8:CD000494

  14. Sheldon WR, Blum J, Durocher J, Winikoff B (2012) Misoprostol for the prevention and treatment of postpartum hemorrhage. Expert Opin Investig Drugs 21:235–250

    CAS  PubMed  Article  Google Scholar 

  15. Smith JM, Gubin R, Holston MM, Fullerton J, Prata N (2013) Misoprostol for postpartum hemorrhage prevention at home birth: an integrative review of global implementation experience to date. BMC Pregnancy Childbirth 13:44

    PubMed Central  PubMed  Article  Google Scholar 

  16. Elati A, Elmahaishi MS, Elmahaishi MO, Elsraiti OA, Weeks AD (2011) The effect of misoprostol on postpartum contractions: a randomised comparison of three sublingual doses. BJOG 118:466–473

    CAS  PubMed  Article  Google Scholar 

  17. Chaudhuri P, Biswas J, Mandal A (2012) Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in low-risk women. Int J Gynaecol Obstet 116:138–142

    CAS  PubMed  Article  Google Scholar 

  18. Singh G, Radhakrishnan G, Guleria K (2009) Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. Int J Gynaecol Obstet 107:130–134

    CAS  PubMed  Article  Google Scholar 

  19. Bellad MB, Tara D, Ganachari MS, Mallapur MD, Goudar SS, Kodkany BS et al (2012) Prevention of postpartum haemorrhage with sublingual misoprostol or oxytocin: a double-blind randomised controlled trial. BJOG 119:975–982; discussion 982–986

    Google Scholar 

  20. Montagu D, Yamey G, Visconti A, Harding A, Yoong J (2011) Where do poor women in developing countries give birth? A multi-country analysis of demographic and health survey data. PLoS ONE 6:e17155

    CAS  PubMed Central  PubMed  Article  Google Scholar 

Download references

Conflict of interest

We declare that we have no conflict of interest. We have full control on primary data and we allow the journal to review our data if requested.

Author information

Affiliations

  1. Department of Obstetrics and Gynecology, Government Medical College and Hospital, Chandigarh, India

    Renu Tewatia & Shikha Rani

  2. Department of Obstetrics and Gynecology, Batra Hospital and Medical Research Center, New Delhi, India

    Usha Srivastav & Bela Makhija

Authors
  1. Renu Tewatia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shikha Rani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Usha Srivastav
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bela Makhija
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shikha Rani.

Additional information

Dr. R. Tewatia was previously working in Department of Obstetrics and Gynecology, Batra Hospital and Medical Research Center, New Delhi.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tewatia, R., Rani, S., Srivastav, U. et al. Sublingual misoprostol versus intravenous oxytocin in prevention of post-partum hemorrhage. Arch Gynecol Obstet 289, 739–742 (2014). https://doi.org/10.1007/s00404-013-3026-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-3026-2

Keywords

  • Uterine hemorrhage
  • Oxytocin
  • Misoprostol
  • Oxytocics